Clinical trials: Haematologic Disease
Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing.
- Conditions
- Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00602225
- Testing
- clofarabine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 (LCL161) works in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential…
- Conditions
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
- Trial name
- NCT02098161
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphocytic Leukemia
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL)…
- Trial name
- NCT01363297
- Testing
- Inotuzumab Ozogamicin
- Where
- 15 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pfizer
Smoldering Multiple Myeloma
Denosumab for Smoldering Multiple Myeloma
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
- Trial name
- NCT03839459
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma
- Trial name
- NCT00719888
- Testing
- Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Fred Hutchinson Cancer Center
Hemophilia B
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
The purpose of this study is to evaluate the safety and dose escalation of SHP648 an adeno-associated viral vector for gene transfer in hemophilia B participants.
- Trial name
- NCT04394286
- Testing
- SHP648
- Where
- 2 sites in Spain, Turkey (Türkiye)
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Neural Tube Defects, Anemia
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders.
- Conditions
- Neural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure
- Trial name
- NCT01392989
- Testing
- CIK cells, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Everett Meyer
Stem Cell Transplantation, Leukemia
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if thiotepa, busulfan, and clofarabine, when given before an…
- Conditions
- Stem Cell Transplantation, Leukemia, Lymphoma
- Trial name
- NCT00857389
- Testing
- Thiotepa, Clofarabine, Busulfan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Clinical Study of WT2725 in Patients With Advanced Malignancies
This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1
- Trial name
- NCT01621542
- Testing
- WT2725
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Multiple Myeloma
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well…
- Trial name
- DFCI 10-106 (NCT01208662)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 46 sites in United States
- Volunteers
- 729 people
- Sponsor
- Paul Richardson, MD
Myelodysplastic Syndromes
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
The primary objective of the trial is to assess the activity of the combined use of Valproic Acid (VPA)in combination with 5-Azacytidine (5-Aza C) in the treatment of MDS.
- Trial name
- NCT00439673
- Testing
- 5-Azacytidine, Valproic Acid, ATRA
- Where
- 7 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00562328
- Testing
- Alemtuzumab, Rituximab, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Sickle Cell Disease
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease.
- Trial name
- NCT01794000
- Testing
- Prasugrel
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 341 people
- Sponsor
- Eli Lilly and Company
Neutropenia
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
This study aims to evaluate the pharmacokinetics of posaconazole (POS) administered intravenously (IV) or orally to immunocompromised pediatric participants.
- Trial name
- NCT02452034
- Testing
- Posaconazole IV solution, Posaconazole powder for oral suspension
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short.
- Trial name
- NCT04905407
- Testing
- Tamibarotene, Venetoclax, Azacitidine
- Where
- 28 sites in United States, France
- Volunteers
- 66 people
- Sponsor
- Syros Pharmaceuticals
Non Malignant Disorders, Immunodeficiencies
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients < 21…
- Conditions
- Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies
- Trial name
- NCT00744692
- Testing
- Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Duke University
Hemophilia A
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII…
- Trial name
- NCT00157157
- Testing
- Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
- Where
- 35 sites in United States, Austria and 8 more
- Volunteers
- 66 people
- Sponsor
- Baxalta now part of Shire
Chronic Phase Myelofibrosis, Primary Myelofibrosis
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase (MPN-AP), or blast phase (MF-BP).
- Conditions
- Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Trial name
- NCT03065400
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- John Mascarenhas
Tumor Lysis Syndrome
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect…
- Trial name
- FLORET (NCT03605212)
- Testing
- Febuxostat
- Where
- 17 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 30 people
- Sponsor
- Menarini Group
Thrombotic Microangiopathies
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
- Trial name
- NCT02222545
- Testing
- OMS721
- Where
- 24 sites in United States, Belgium and 10 more
- Volunteers
- 58 people
- Sponsor
- Omeros Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.